mavrilimumab   Click here for help

GtoPdb Ligand ID: 7785

Synonyms: CAM-3001 | KPL-301
Immunopharmacology Ligand
Compound class: Antibody
Comment: Mavrilimumab targets CSF2RA (aka GM-CSFRα).
Peptide sequences for this antibody are available from its IMGT/mAb-DB record. Peptide sequence analysis identifies mavrilimumab as antibody 6 in patent US8263075 [2].
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
Bioactivity Comments
Results presented in patent US8263075 [2] show that mavrilimumab (antibody 6) has potent effects in biological assays, including inhibition of GM-CSF-induced proliferation of TF-1 ( human erythroleukemic) cells and activity in GM-CSF-induced shape change assays using human granulocytes.
Selectivity at catalytic receptors
Key to terms and symbols Click column headers to sort
Target Sp. Type Action Value Parameter Concentration range (M) Reference
GM-CSF receptor, α subunit Primary target of this compound Hs Antibody Binding 9.9 pIC50 - 2
⤷ pIC50 9.9 (IC50 1.39x10-10 M) [2]